Table 5.

Summary of adverse events

	Dolutegravir (n = 32)	Dolutegravir + boceprevir (n = 16)	Dolutegravir + telaprevir (n = 16)
All adverse events*
Any adverse event	4 (13)	9 (56)	11 (69)
Headache	2 (6)	1 (6)	5 (31)
Anorectal discomfort	0	2 (13)	2 (13)
Dysgeusia	0	2 (13)	1 (6)
Maculopapular rash	1 (3)	0	2 (13)
Abdominal pain	0	0	2 (13)
Anal haemorrhage	0	0	2 (13)
Haemorrhoids	0	0	2 (13)
Drug-related adverse events*
Any adverse event	2 (6)	5 (31)	7 (44)
Headache	1 (3)	0	4 (25)
Dysgeusia	0	2 (13)	1 (6)
Maculopapular rash	1 (3)	0	2 (13)
Abdominal pain	0	0	2 (13)

^*Occurring in two or more subjects in any treatment group. Presented as n (%).